Aratana Therapeutics (NASDAQ:PETX) Downgraded to Strong Sell at BidaskClub

BidaskClub cut shares of Aratana Therapeutics (NASDAQ:PETX) from a sell rating to a strong sell rating in a report issued on Saturday, July 6th, BidAskClub reports.

Several other research analysts also recently issued reports on the stock. HC Wainwright reiterated a buy rating on shares of Oragenics in a research report on Friday, April 26th. Zacks Investment Research downgraded shares of HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. Finally, Credit Suisse Group raised ConocoPhillips from a neutral rating to an outperform rating and set a $75.00 price target for the company in a research note on Tuesday, April 30th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the stock. The stock currently has an average rating of Hold and an average price target of $5.08.

NASDAQ PETX opened at $4.98 on Friday. The company has a 50 day simple moving average of $4.93. Aratana Therapeutics has a 12-month low of $3.30 and a 12-month high of $7.16.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04). Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. The firm had revenue of $7.36 million during the quarter, compared to analyst estimates of $6.98 million. Equities research analysts predict that Aratana Therapeutics will post -0.31 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its holdings in shares of Aratana Therapeutics by 1.6% during the fourth quarter. Northern Trust Corp now owns 515,994 shares of the biopharmaceutical company’s stock worth $3,163,000 after buying an additional 8,135 shares in the last quarter. Atlas Capital Advisors LLC bought a new position in shares of Aratana Therapeutics in the first quarter worth $69,000. Impax Asset Management Group plc bought a new position in shares of Aratana Therapeutics in the fourth quarter worth $221,000. Highland Private Wealth Management increased its position in shares of Aratana Therapeutics by 35.0% in the first quarter. Highland Private Wealth Management now owns 13,500 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 3,500 shares during the period. Finally, BlackRock Inc. increased its position in shares of Aratana Therapeutics by 5.5% in the fourth quarter. BlackRock Inc. now owns 3,629,595 shares of the biopharmaceutical company’s stock worth $22,249,000 after purchasing an additional 190,011 shares during the period. 65.00% of the stock is owned by institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

Featured Article: Investing in Growth Stocks

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.